Of randomised controlled trials; 2012. Dias S, Sutton AJ, Welton NJ, Ades AE: Good DSU Technical Help Document three: Heterogeneity: subgroups, meta- regression, bias and bias-adjustment; 2012. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ: Addressing betweenstudy heterogeneity and inconsistency in mixed therapy comparisons: Application to stroke prevention therapies in people with non-rheumatic atrial fibrillation. Stat Med 2009, 28:1861?881. Dias S, Welton NJ, Caldwell DM, Ades AE: Checking consistency in mixed remedy comparison meta-analysis. Stat Med 2010, 29:932?44. Lunn DJ, Thomas A, Greatest N, Spiegelhalter D: WinBUGS ?a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000, ten:325?37. Dickson D, Hosie G, English J: The Primary Care Rheumatology Society OA Knee Study Group: a double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. Clin Res 2001, 4:41?two. Abou-Raya S, Abou-Raya A, Helmii M: Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing 2012, 41:646?52. Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, Steup A, Lange B, Rauschkolb C, Haeussler J: Efficacy and security of tapentadol extended release compared with oxycodone controlled release for the management of moderate to serious chronic discomfort associated to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010, 30:489?05. Baerwald C, Verdecchia P, Duquesroix B, Frayssinet H, Ferreira T: Efficacy, security, and effects on blood stress of naproxcinod 750 mg twice day-to-day compared with placebo and naproxen 500 mg twice every day in sufferers with osteoarthritis of your hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum 2010, 62:3635?644. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson Pc, Verburg KM, Geis GS: Remedy of osteoarthritisMyers et al. BMC Musculoskeletal Problems 2014, 15:76 http://biomedcentral/1471-2474/15/Page 16 of53.54.55.56.57.58.59.60.61.62.63.64.65.66.67.68.69.with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999, 74:1095?105. Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O’Brien K, Tershakovec AM: Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg inside the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority research. Rheumatology (Oxford) 2007, 46:496?07. Boswell DJ, Ostergaard K, Philipson RS, Hodge RA, Blum D, Brown JC, Quessy SN: Evaluation of GW406381 for therapy of osteoarthritis on the knee: two randomized, controlled research.Fmoc-L-Ala(BCP)-OH structure Medscape J Med 2008, ten:259.tert-Butyl 2-(3-aminophenyl)acetate web Burch F, Fishman R, Messina N, Corser B, Radulescu F, Sarbu A, Craciun-Nicodin MM, Chiriac R, Beaulieu A, Rodrigues J: Other individuals: A comparison from the analgesic efficacy of Tramadol Contramid OAD versus placebo in individuals with pain as a consequence of osteoarthritis.PMID:25023702 J Discomfort Symptom Handle 2007, 34:328?38. Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM, Bradley JD, Bingham CO, Weisman MH, Jackson CG, Lane NE, Cush JJ, Moreland LW, Schumacher HR, Oddis CV, Wolfe F, Molitor JA, Yocum DE, Schnitzer TJ, Furst DE, Sawitzke AD, Shi H, Brandt KD, Moskowitz RW, Williams HJ: Glucosamine, chondroitin sulfate, plus the two in combination for painful knee o.